Evidence map›Paper›PMID 37770581›Full record

ArticleScientific reports2023

Differential roles of highly expressed PFKFB4 in colon adenocarcinoma patients.

Xiaojing Gu, Xingchen Dai, Yongli Huang, Yuhuan Zhang, Lintao Dong, Chanchan Gao, Fang Wang

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xiaojing Gu *Department of Gastroenterology, General Hospital, Ningxia Medical University, Yinchuan, Ningxia, China.
Xingchen Dai *Department of Gastroenterology, General Hospital, Ningxia Medical University, Yinchuan, Ningxia, China.
Yongli Huang *Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, China.
Yuhuan ZhangDepartment of Gastroenterology, General Hospital, Ningxia Medical University, Yinchuan, Ningxia, China.
Lintao DongDepartment of Gastroenterology, General Hospital, Ningxia Medical University, Yinchuan, Ningxia, China.
Chanchan GaoDepartment of Oncology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China. gaochanchan1981@163.com.
Fang WangDepartment of Gastroenterology, General Hospital, Ningxia Medical University, Yinchuan, Ningxia, China. wangfang9803@163.com.
Ningxia Medical University · CNNingxia Medical University General Hospital · CNZhongda Hospital Southeast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colon adenocarcinoma (COAD) is a common malignant tumor, and the role of the protein PFKFB4 in glycolysis and pentose phosphate pathways is crucial. Researchers investigated the clinical significance of PFKFB4 in COAD by studying its expression in 79 tissue samples using immunohistochemistry. We found that PFKFB4 expression was significantly higher in COAD patients, particularly in the sigmoid colon. Interestingly, high PFKFB4 expression was associated with both improved overall survival (OS) and worse progression-free survival (PPS) in COAD patients. Further analysis revealed that genes associated with PFKFB4 were linked to various metabolic pathways, including amino acid biosynthesis, glycolysis, gluconeogenesis, glucose metabolism, and inflammatory response. PFKFB4 expression also showed correlations with the infiltration of different immune cell types in COAD patients, such as CD8+ T cells, CD4+ T cells, regulatory T cells (Tregs), macrophages, neutrophils, dendritic cells, active mast cells, and resting NK cells. Overall, the relationship between PFKFB4 expression and the prognosis of COAD is complex and diverse, possibly playing different roles at different stages of the disease. Moreover, its mechanism might involve interactions with various metabolic pathways and immune infiltration in the tumor microenvironment. These findings provide valuable insights into the potential role of PFKFB4 as a biomarker or therapeutic target in COAD.

Indexed as

AdenocarcinomaColonic NeoplasmsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesColon, SigmoidHumansPhosphofructokinase-2PrognosisTumor MicroenvironmentPFKFB4 protein, humanPhosphofructokinase-2

Identifiers

PMID37770581
PMCPMC10539362
OpenAlexW4387136429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.